Could fewer shots keep myeloma in check? new trial aims to cut costs
Disease control
Not yet recruiting
This study tests whether giving the drug daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide is as effective as the standard every-4-week schedule for people with multiple myeloma after a stem cell transplant. The goal is to reduce treatment burden…
Phase: PHASE2 • Sponsor: Eden Biltibo • Aim: Disease control
Last updated May 14, 2026 12:04 UTC